Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by GarthCinammonon Dec 06, 2016 2:26pm
246 Views
Post# 25561547

RE:RE:Shorters

RE:RE:ShortersPersonal,

Below I've attached a couple paragraphs from Beacon securities report following analyst day.  Might be of some comfort for you? Seems to be widely know that PLI is being shorted heavily and the shorters are currently driving the share price where they want it!
  • Perhaps the major concern of investors and the cause of the recent share weakness is the balance sheet. With ~12 months of cash at the current burn rate, the market is pricing in the risk of another equity financing. We believe such concern is premature as the upside risk of a partnership (both on Pg and PBI-4050) is real. Such an announcement would quickly reverse the current malaise and could also result in a significant short-covering rally.
     

    During the analyst day in New York City last week, the stock started to drop (from $2.83 to $2.63) as soon as the company posted a slide about its proposed UK manufacturing expansion, which could add 600,000 1 million litres of capacity. Such a facility would almost double ProMetic’s current capacity. Clearly there was/is concern about how the company would pay for such a UK facility on top of all of its other R&D commitments.

    Garth

     


     

Bullboard Posts